ES3036969T3 - Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases - Google Patents
Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseasesInfo
- Publication number
- ES3036969T3 ES3036969T3 ES20956217T ES20956217T ES3036969T3 ES 3036969 T3 ES3036969 T3 ES 3036969T3 ES 20956217 T ES20956217 T ES 20956217T ES 20956217 T ES20956217 T ES 20956217T ES 3036969 T3 ES3036969 T3 ES 3036969T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- compound
- formula
- salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/037048 WO2022070289A1 (ja) | 2020-09-30 | 2020-09-30 | ピリミジン含有含窒素二環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3036969T3 true ES3036969T3 (en) | 2025-09-25 |
Family
ID=80951519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20956217T Active ES3036969T3 (en) | 2020-09-30 | 2020-09-30 | Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12590090B2 (https=) |
| EP (1) | EP4223750B1 (https=) |
| JP (1) | JP7433463B2 (https=) |
| KR (1) | KR20230084145A (https=) |
| CN (1) | CN116194454B (https=) |
| AU (1) | AU2020471055B8 (https=) |
| CA (1) | CA3194164A1 (https=) |
| ES (1) | ES3036969T3 (https=) |
| MX (1) | MX2023003698A (https=) |
| PL (1) | PL4223750T3 (https=) |
| WO (1) | WO2022070289A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110003219A (zh) | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| RU2632900C2 (ru) * | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| US9169260B2 (en) * | 2011-03-22 | 2015-10-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| EP2691399B1 (en) | 2011-03-28 | 2016-07-13 | F.Hoffmann-La Roche Ag | Thiazolopyrimidine compounds |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| EP2802590B1 (en) | 2012-01-10 | 2017-03-01 | F. Hoffmann-La Roche AG | Thienopyrimidine compounds |
| CN104169275B (zh) * | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| RU2548363C2 (ru) | 2012-01-25 | 2015-04-20 | Общество с ограниченной ответственностью "Асинэкс Медхим." | СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Haspin киназы |
| CN106232122A (zh) | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
| CN108473498B (zh) * | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| CN106946890A (zh) * | 2017-04-26 | 2017-07-14 | 中国药科大学 | 吡啶类irak4抑制剂、其制备方法及应用 |
| AU2018346051B2 (en) * | 2017-10-02 | 2022-11-10 | 1st Biotherapeutics Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
| WO2022070288A1 (ja) * | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | 含窒素二環化合物 |
-
2020
- 2020-09-30 MX MX2023003698A patent/MX2023003698A/es unknown
- 2020-09-30 EP EP20956217.2A patent/EP4223750B1/en active Active
- 2020-09-30 WO PCT/JP2020/037048 patent/WO2022070289A1/ja not_active Ceased
- 2020-09-30 KR KR1020237010766A patent/KR20230084145A/ko not_active Ceased
- 2020-09-30 US US18/029,289 patent/US12590090B2/en active Active
- 2020-09-30 CA CA3194164A patent/CA3194164A1/en active Pending
- 2020-09-30 CN CN202080105488.8A patent/CN116194454B/zh active Active
- 2020-09-30 ES ES20956217T patent/ES3036969T3/es active Active
- 2020-09-30 JP JP2022553287A patent/JP7433463B2/ja active Active
- 2020-09-30 PL PL20956217.2T patent/PL4223750T3/pl unknown
- 2020-09-30 AU AU2020471055A patent/AU2020471055B8/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022070289A1 (ja) | 2022-04-07 |
| JP7433463B2 (ja) | 2024-02-19 |
| US12590090B2 (en) | 2026-03-31 |
| AU2020471055B8 (en) | 2023-12-21 |
| CN116194454B (zh) | 2025-02-18 |
| PL4223750T3 (pl) | 2025-09-15 |
| EP4223750A4 (en) | 2024-06-19 |
| CA3194164A1 (en) | 2022-04-07 |
| JPWO2022070289A1 (https=) | 2022-04-07 |
| AU2020471055B2 (en) | 2023-12-14 |
| KR20230084145A (ko) | 2023-06-12 |
| MX2023003698A (es) | 2023-06-15 |
| CN116194454A (zh) | 2023-05-30 |
| US20240025893A1 (en) | 2024-01-25 |
| EP4223750A1 (en) | 2023-08-09 |
| EP4223750B1 (en) | 2025-06-25 |
| AU2020471055A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2924362C (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| JP7847123B2 (ja) | 化合物、組成物及び方法 | |
| HK1223100A1 (zh) | 杂环化合物 | |
| WO2012121939A2 (en) | Aminopyrazine compounds | |
| EA030695B1 (ru) | Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич | |
| KR20140096100A (ko) | 이환 피페라진 화합물 | |
| JP6192741B2 (ja) | 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤 | |
| BR112020018094A2 (pt) | Compostos de aminopirazina diol como inibidores de pi3k-¿ | |
| TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
| ES2763344T3 (es) | Inhibidores macrocíclicos de la cinasa RIP2 | |
| CN117120435A (zh) | Abhd6拮抗剂 | |
| ES3036969T3 (en) | Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases | |
| RU2827867C1 (ru) | Пиримидин- и азотсодержащее бициклическое соединение | |
| ES3033780T3 (en) | Macrocyclic compounds incorporating piperidine and quinoline or qunaxoline as irak-4 inhibitors for the treatment of inflammatory conditions | |
| TWI898106B (zh) | 含有嘧啶之含氮雙環化合物 | |
| CA3194090C (en) | Polycyclic macrocyclic compounds and their use in irak-4 inhibition | |
| RU2818822C1 (ru) | Макроциклическое соединение | |
| WO2025155786A1 (en) | Bicyclic tyrosine kinase 2 inhibitors and uses thereof | |
| CA3114259A1 (en) | Aminonorbornane derivative and manufacture method therefor and use thereof |